Intravenous Fosfomycin: An Assessment of Its Potential for Use in the Treatment of Systemic Infections in Canada

Table 2

In vitro activity of fosfomycin against aerobic and facultative Gram-positive bacteria (cumulative data from [13, 29, 31–34]).

Organism	Fosfomycin
	Number of isolates tested	MIC50 (µg/mL)	MIC90 (µg/mL)	Range (µg/mL)
Enterococcus faecalis	1965	32–64	64	0.5–512
Enterococcus faecium	620	32–64	64–128	0.5–128
Enterococcus spp.	137	16–32	64	0.25–>256
Staphylococcus aureus	2213	4	16	0.12–512
Staphylococcus aureus, MSSA	103	4	4	0.5–16
Staphylococcus aureus, MRSA	263	4	8–64	0.5–512
Staphylococcus epidermidis	896	8	128	0.5–256
Staphylococcus saprophyticus	309	64–128	256–>512	2–>512
Streptococcus pneumoniae	57	8	16	4–32
Streptococcus pyogenes	150	32	64	2–64
Streptococcus agalactiae	154	8–32	64	1–64